Roche's Unintentional Release of Promising Lung Cancer Drug Trial Results
Swiss pharmaceutical company Roche inadvertently published positive interim trial data on its lung cancer drug, tiragolumab, which showed a 19% lower mortality rate for patients on the drug compared to those without it. While the data is not yet statistically significant, researchers will continue to gather trial data, with more solid survival results expected to be published in early 2024. The disclosure boosted Roche's shares by 5% and also led to an increase in the shares of other companies testing anti-TIGIT drugs.